+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
FEMALE
ID07542730

Evaluating Intravenous Diphenhydramine as an Addition to Moderate Sedation for Pain Control During First Trimester Procedural Abortions

Led by University of Rochester · Updated on 2026-08-21

98

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate whether adding intravenous diphenhydramine to a standard moderate sedation regimen improves pain control during first trimester procedural abortion. The study focuses on participants undergoing uterine aspiration at less than 13 weeks gestation. It is a single center, double blind, randomized controlled trial designed to assess pain and sedation levels during the procedure. Participants will be randomly assigned to receive either intravenous diphenhydramine 50 mg or a matching placebo before the uterine aspiration, along with standard moderate sedation using midazolam and fentanyl. Additional doses of midazolam and fentanyl may be given as needed during the procedure. The trial maintains blinding for participants, clinical staff, and outcome assessors. Participants will report pain using a 100 mm Visual Analog Scale at multiple points during and after the procedure. Sedation depth will be measured using the Modified Observers Assessment of Alertness Sedation scale. Researchers will also monitor sedative medication doses, time to readiness for discharge, and any sedation-related adverse events. The study is expected to complete in February 2027.

CONDITIONS

Brief Title

Diphenhydramine as an Adjunct to Moderate Sedation for Procedural First Trimester Abortions

Research Team

S

Sarah Cavegila, MPH

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here